Company: BIAF
Filing Date: 2025-09-24
Form Type: S-1
Source: 0001493152-25-014730
Chunk: 14

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-09-24
Form: S-1
Chunk 14
---
 Common Stock and pay the stated exercise price per share.

| 9 |

If we are required to obtain Warrant Shareholder Approval, until we are able to receive such approval the Common Stock Purchase Warrants will not be exercisable, and if we are unable to obtain such approval the Common Stock Purchase Warrants will have no value.

If we are required to obtain Warrant Shareholder Approval, the Common Stock Purchase Warrants will not be exercisable until, and unless, we obtain the Warrant Shareholder Approval from our shareholders. While we intend to promptly seek shareholder approval, if required, there is no guarantee that the Warrant Shareholder Approval will ever be obtained. If we are unable to obtain the Warrant Shareholder Approval, the Common Stock Purchase Warrants will have no value. In addition, we will incur substantial cost, and management will devote substantial time and attention, in attempting to obtain the Warrant Shareholder Approval.

Holders of our Common Stock Purchase Warrants and Pre-Funded Warrants will have no rights as a Common Stockholder until such holders exercise their Common Stock Purchase Warrants or Pre-Funded Warrants and acquire our Common Stock, except as otherwise provided in the Common Stock Purchase Warrants and the Pre-Funded Warrants.

Until holders of the Common Stock Purchase Warrants and the Pre-Funded Warrants acquire shares of our Common Stock upon exercise thereof, holders of the Common Stock Purchase Warrants and the Pre-Funded Warrants will have no rights with respect to the shares of our Common Stock, except as otherwise provided in the Common Stock Purchase Warrants and the Pre-Funded Warrants. Upon exercise of the Common Stock Purchase Warrants and the Pre-Funded Warrants, such holders will be entitled to exercise the rights of a Common Stockholder only as to matters for which the record date occurs after the exercise date.

Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.

In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement including: (i) timely delivery of shares; (ii) agreement to not enter into variable rate financings for one year from closing, subject to an